Clinical outcome of myelodysplastic syndrome progressing on hypomethylating agents with evolving frontline therapies: continued challenges and unmet needs
Blood Cancer J
.
2022 Jun 24;12(6):93.
doi: 10.1038/s41408-022-00691-9.
Authors
Ahmad Ghorab
1
,
Aref Al-Kali
2
,
Michelle Elliot
2
,
Naseema Gangat
2
,
Hasan Alkhateeb
2
,
Mithun Shah
2
,
Yuanhang Liu
3
,
Cecilia Arana Yi
4
,
Hemant Murthy
1
,
Mohamed Kharfan-Dabaja
1
,
Ayalew Tefferi
2
,
Mrinal Patnaik
2
,
Mark Litzow
2
,
Talha Badar
5
Affiliations
1
Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL, USA.
2
Division of Hematology, Mayo Clinic, Rochester, MN, USA.
3
Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
4
Division of Hematology and Oncology, Mayo Clinic, Phoenix, AZ, USA.
5
Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL, USA. badar.talha@mayo.edu.
PMID:
35750664
PMCID:
PMC9232594
DOI:
10.1038/s41408-022-00691-9
No abstract available
Publication types
Letter
MeSH terms
Antimetabolites, Antineoplastic / therapeutic use
DNA Methylation
Humans
Myelodysplastic Syndromes* / drug therapy
Myelodysplastic Syndromes* / genetics
Substances
Antimetabolites, Antineoplastic